Abbott announced two important CE marks, expanding access to the company’s TriClip minimally invasive tricuspid valve repair technology and its market-leading Xience everolimus-eluting coronary stent.
On 8 April, Abbott announced it received a CE mark for the TriClip G4, the next-generation version of its TriClip...






